“…Analyzing the data by continent, the following vaccination intention prevalences were found: In Asian countries, it was 64% (95% CI: 53-74%; 13883 participants; 17 studies; I 2 = 99%) (17, 18, 20, 22, 24-27, 29, 34, 35, 37, 39-42, 44); in African countries, it was 43% (95% CI: 39-47%; 1538 participants; 3 studies; I 2 = 53%) (19,23,28); in European countries, it was 62% (95% CI: 45-78%; 35811 participants; 6 studies; I 2 = 99%) (21, 30-32, 36, 38); and in American countries, it was 63% (95% CI: 32-89%; 1426 participants; 3 studies; I 2 = 99%) (16, 33, 43) (Figure S2). Furthermore, when focusing on the target population of the studies, the following vaccination intention prevalences against Mpox were observed: among the general population, it was 54% (95% CI: 45-62%; 10296 participants; 11 studies; I 2 = 99%) (18, 19,22,23,25,26,29,[39][40][41]43); among healthcare workers, it was 57% (95% CI: 33-79%; 3333 participants; 10 studies; I 2 = 99%) (17,24,28,30,33,35,37,38,42,44); and among the LGBTI community, it was 76% (95% CI: 70-82%;39029 participants; 8 studies; I 2 = 98%) (16, 20,21,27,31,32,34,36) (Figure S4).…”